-
High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib
Kuiper, J. L., Heideman, D. A. M., Thunnissen, E., van Wijk, A. W., Postmus, P. E. & Smit, E. F., May 2014, In: European Journal of Cancer. 50, 7, p. 1399-401 3 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
Kuiper, J. L., Heideman, D. A. M., Thunnissen, E., Paul, M. A., van Wijk, A. W., Postmus, P. E. & Smit, E. F., 2014, In: Lung Cancer. 85, 1, p. 19-24Research output: Contribution to journal › Article › Academic › peer-review
-
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation
Dingemans, A-M. C., Mellema, W. W., Groen, H. J. M., van Wijk, A., Burgers, S. A., Kunst, P. W. A., Thunnissen, E., Heideman, D. A. M. & Smit, E. F., 2013, In: Clinical Cancer Research. 19, 3, p. 743-751Research output: Contribution to journal › Article › Academic › peer-review
- All publications
